News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fosun Pharma Subsidiary to In-License Diabetes Drug From Canadian Pharma



8/20/2013 8:27:17 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 19, 2013 -- Wanbang Pharma, a subsidiary of Fosun Pharma, has signed a Letter of Intent to in-license China rights for a diabetes 2 treatment from Sirona Biochem of Canada. The molecule is a member of a new class of oral diabetes drugs known as SGLT2 inhibitors. Wanbang, which will be responsible for obtaining CFDA approval of the drug, will pay up to $9.5 million in upfront and regulatory milestones to Sirona plus royalties, once the drug enters the marketplace. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (TSX: SBM)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES